ARSENALBIO
ArsenalBio is building a programmable cell therapy company to create highly effective and accessible immune cell therapies to impact outcomes for a much broader number of patients, initially those with cancer. Founded in 2019, ArsenalBio is focused on integrating technologies such as CRISPR-based genome engineering, scaled and high throughput target identification, synthetic biology, and machine learning to advance a new paradigm to discover and develop immune cell therapies. With its programmable and computationally driven approach, ArsenalBio aspires to evolve critical metrics of success for immune cell therapies, including enhanced and broader efficacy, increased patient safety, reduced provider costs, and expanded market access.
ARSENALBIO
Industry:
Biotechnology Cloud Computing Life Science Medical
Founded:
2019-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.arsenalbio.com
Total Employee:
251+
Status:
Active
Contact:
650-240-8844
Total Funding:
305.81 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving Euro Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Analytics Content Delivery Network Global Site Tag
Similar Organizations
BioFlyte
BioFlyte is a biodefense company created to commercialize a revolutionary new class of fieldable biological threat collection.
Calimmune
Calimmune is a clinical-stage gene therapy company.
EcoPlant
EcoPlant is a cloud based platform.
ExCellThera
ExCellThera is an advanced clinical stage biotechnology company.
Hemostemix
Hemostemix is a public clinical-stage biotechnology company.
Quell Therapeutics
Quell Therapeutics is a cell therapy company
Stemson Therapeutics
Stemson Therapeutics is a pre-clinical stage cell therapy company.
Turnstone Biologics
Turnstone Biologics is a privately-held clinical stage biotech company.
Aria Pharmaceuticals
Aria Pharmaceuticals is a artificial intelligence-driven biopharmaceutical company.
Current Advisors List
Current Employees Featured
Founder
Investors List
Euclidean Capital
Euclidean Capital investment in Series B - ArsenalBio
Parker Institute for Cancer Immunotherapy
Parker Institute for Cancer Immunotherapy investment in Series B - ArsenalBio
Bristol-Myers Squibb
Bristol-Myers Squibb investment in Series B - ArsenalBio
Emerson Collective
Emerson Collective investment in Series B - ArsenalBio
Westlake Village BioPartners
Westlake Village BioPartners investment in Series B - ArsenalBio
Kleiner Perkins
Kleiner Perkins investment in Series B - ArsenalBio
University of California, San Francisco
University of California, San Francisco investment in Series B - ArsenalBio
Triatomic Capital
Triatomic Capital investment in Series B - ArsenalBio
Hitachi Ventures
Hitachi Ventures investment in Series B - ArsenalBio
SoftBank Vision Fund
SoftBank Vision Fund investment in Series B - ArsenalBio
Key Employee Changes
| Date | New article |
|---|---|
| 2021-07-19 | ArsenalBio Strengthens Leadership Team with the Appointment of W. Nicholas Haining, BM, BCh, as Chief Scientific Officer |
Official Site Inspections
http://www.arsenalbio.com Semrush global rank: 1.54 M Semrush visits lastest month: 15.56 K
- Host name: 151.101.194.159
- IP address: 151.101.194.159
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "ArsenalBio"
About - Arsenal Bio
Susie is a founding member of the Chicago chapter of Chief, an organization dedicated to supporting, empowering, and mentoring women C-suite leaders. Irene Pleasure, PhD, JD. ...See details»
ArsenalBio - Crunchbase Company Profile & Funding
ArsenalBio is building a programmable cell therapy company to create highly effective and accessible immune cell therapies to impact outcomes for a much broader number of patients, initially those with cancer. Founded in 2019, …See details»
Values - About Us
This is ArsenalBio. This is our Company. Ken Drazan, MD Founding CEO. Our Values. One Team We prioritize the team’s outcomes over individual goals to achieve our company mission together Transparency We operate with open …See details»
ArsenalBio - Leadership Team - The Org
The Leadership Team at ArsenalBio is responsible for steering the company's strategic vision and operational execution in the development of innovative cellular therapies for chronic diseases, …See details»
Arsenal Biosciences, Inc. | LinkedIn
Arsenal Biosciences, Inc. | 22,491 followers on LinkedIn. ArsenalBiosciences, Inc., is a clinical stage programmable cell therapy company focused on the realization of solid tumor cell therapy to ...See details»
All the Right Ingredients: A Q&A with the Founders of ArsenalBio
Jun 24, 2021 That’s the case for ArsenalBio, a company whose scientific founders – members of the PICI network – began with their own ideas on how to overcome the challenges of treating …See details»
ArsenalBio emerges from stealth with $85 million and a
Oct 17, 2019 The story behind ArsenalBio begins with Sean Parker’s Institute for Cancer Immunotherapy.. Founded in 2016, the Institute has been instrumental in providing a space for …See details»
BMS-backed Arsenal Bio pulls trigger on $220M series B, touting ...
Sep 6, 2022 This approach has already been put to the test via the company’s collaboration with BMS, made back in January last year. In exchange for $70 million in upfront cash plus …See details»
ArsenalBio raises $325M in one of the year’s largest biotech …
Sep 4, 2024 ArsenalBio’s Series C round goes against that trend. Data compiled by BioPharma Dive show the funding is the fourth largest among biotech startups this year, trailing only Xaira …See details»
ArsenalBio - Funding, Financials, Valuation & Investors - Crunchbase
ArsenalBio is a programmable cell therapy company that offers CAR T-cell therapies for solid tumors. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. ... How much …See details»
Thermo Fisher and ArsenalBio Advancing Clinical Manufacturing …
Apr 3, 2023 ArsenalBio recently advanced its lead product candidate into clinical manufacturing of its autologous integrated circuit T cell (ICT) therapy for platinum-resistant ovarian cancer. …See details»
ArsenalBio Strengthens Leadership Team with the Appointment of …
Jul 19, 2021 “ArsenalBio has laid out a vision and a roadmap for engineering the fate and function of T cells to help cure cancer. ... He also led a multi-disciplinary organization at Merck …See details»
ArsenalBio raises $325M, pivots away from former lead asset
Sep 4, 2024 Packing up and moving on . Those programs take aim at kidney and prostate cancers, while ArsenalBio pushes aside former lead asset AB-1015, a CAR T-cell therapy …See details»
Arsenal Biosciences Closes $220 Million Series B ... - Business Wire
Sep 6, 2022 Arsenal Biosciences, Inc. (ArsenalBio), headquartered in South San Francisco, Calif., is a privately held programmable cell therapy company discovering and developing a …See details»
ArsenalBio Launches With $85 Million Series A Financing to
Oct 17, 2019 ArsenalBio’s management team includes seasoned industry executives who bring immuno-oncology, cell therapy and genomic expertise: Ken Drazan, MD, who most recently …See details»
Invest In ArsenalBio Stock | Buy Pre-IPO Shares - EquityZen
Oct 1, 2024 ArsenalBio is building a programmable cell therapy company to create highly effective and accessible immune cell therapies to impact outcomes for a much broader …See details»
Technology - Arsenal Bio
ArsenalBio deploys a synthetic biology toolkit to genetically program a patient’s own T cells to potentially eradicate solid tumors. To address the multi-faceted problem of cancer, we believe …See details»
ArsenalBio Announces Multi-Program Discovery ... - Business Wire
Jan 7, 2021 ArsenalBio is a privately held, programmable cell therapy company focused on the realization of solid tumor cell therapy by helping more patients fight cancer and saving lives.See details»
Pipeline - Arsenal Bio
ArsenalBio and Genentech are deploying synergistic capabilities to study effective T cell-based modifications and develop new understandings of their effects through preclinical analysis. …See details»